Home Infusion Therapy for PI – How Does Sub-Q Ig Work?

Vivaglobin 16% is the first and only 16% Sub-Q Ig therapy available for patients with primary immunodeficiency

You and your family can be extremely busy, and traditional IVIg infusion therapy can be time-consuming. But Ig replacement therapy needn't take away from your quality time.

Vivaglobin^® is a subcutaneous (Sub-Q) immunoglobulin (Ig) therapy that makes self-administration possible in the comfort of your home, giving you greater freedom and flexibility in your treatment schedule. Home infusion therapy may reduce interruptions in work, school, and social schedules, allowing you to schedule treatments around your life—not schedule your life around appointments.

Sub-Q Ig therapy is infused into the fatty tissue just below the skin, instead of into a vein. Sub-Q Ig needles are small and are available in varying lengths to accommodate different patient needs.

Sub-Q Ig can be infused on a weekly basis while you’re at home, at work or on-the-go, using a small, portable infusion pump. Infusion sites include the thighs, upper arms, stomach, or hips—anywhere you can "pinch an inch."

Learning how to administer Sub-Q Ig home infusion therapy is simple, and your doctor or nurse can begin to teach you this process during your first infusion.

Click here to watch a self-administration video that demonstrates the proper techniques for infusing Vivaglobin^® 16% at home.

Next: Moving to Sub-Q Ig

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is a prescription treatment for patients with primary immunodeficiency (PI).

Immune globulin products, such as Vivaglobin, should not be taken by individuals with a history of anaphylactic or severe systemic response to immune globulin (Ig) preparations. If you feel you are having a severe reaction, discontinue treatment immediately and inform your doctor.

Vivaglobin is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent side effect was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events, regardless of cause, included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.

Patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions, including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock.

Ig administration may impair the effect of virus vaccines, such as measles, mumps and rubella. Before getting any vaccination, inform your doctor that you are using Vivaglobin.

In clinical studies, administration of Vivaglobin has been shown to be safe and well tolerated in pediatric subjects without adjusted dosing. Safety and effectiveness were not studied in children under 2 years of age.

Please see full prescribing information and patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.